# EDGAR Filing Document

**Accession Number:** 0001833141
**File Stem:** 0001628280-25-031005
**Filing Date:** 2025-6
**Character Count:** 4518
**Document Hash:** a319f073d7fc049e780b7dc512b48963
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-031005.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001628280-25-031005

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250612

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CYBIN INC.
- **CENTRAL INDEX KEY:** 0001833141
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40673
- **FILM NUMBER:** 251043179

**BUSINESS ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9
- **BUSINESS PHONE:** (908) 764-8385

**MAIL ADDRESS:**
- **STREET 1:** 100 KING STREET WEST
- **STREET 2:** SUITE 5600
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5X 1C9

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**<br>**Form 6-K**<br>**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**<br>

For the month of June, 2025.

Commission File Number: **001-40673**

****<br>**<u>Cybin Inc.</u>**<br>(Exact Name of Registrant as Specified in Charter)<br>**100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9** 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br>

---

| | | | |
|:---|:---|:---|:---|
| | | **CYBIN INC.** | **CYBIN INC.** |
| | | (Registrant) | (Registrant) |
| Date: | June 12, 2025 | By: | */s/ Doug Drysdale&nbsp;&nbsp;&nbsp;&nbsp;*  |
|  |  | Name: | Doug Drysdale |
|  |  | Title: | Chief Executive Officer |

---

------

**<u>EXHIBIT INDEX</u>**

99.1 <u>[News Release dated June 12, 2025](a06-12x2025hcwneuroperspec.htm)</u>

## Exhibit 99.1

![image_0.jpg](image_0.jpg)

 **Cybin to Participate in the H.C. Wainwright 6**<sup>th</sup> **Annual Neuro Perspectives Conference**

<br>**TORONTO, CANADA** – June 12, 2025 – <u>Cybin Inc.</u> (NYSE American:CYBN) (Cboe CA:CYBN) ("**Cybin**" or the "**Company**"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 6<sup>th</sup> Annual Neuro Perspectives Conference, taking place June 16-17, 2025 .

Mr. Drysdale's fireside chat will be available on demand beginning on Monday, June 16, 2025, at 7:00 a.m. ET. To listen to the event, please <u>click here</u> to access the webcast. The archived webcast will also be available on the Company's investor relations website on the <u>Events & Presentations</u> page.

**About Cybin**

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

------

**Investor & Media Contact:** 

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

<u>irteam@cybin.com</u> – or – <u>media@cybin.com</u> 

<br>